Can eye movement therapy ease trauma in thyroid cancer patients?
NCT ID NCT07447089
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This pilot study is testing whether a therapy called EMDR (eye movement desensitization and reprocessing) can help reduce post-traumatic stress and psychological distress in people with advanced thyroid cancer. The study will enroll 25 participants who have cancer and PTSD symptoms. They will receive group and individual EMDR sessions. The goal is to see if this approach is feasible and helpful.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- EMDR therapy (eye movement desensitization and reprocessing)
- What this could lead to
- If it works, this could offer a way to reduce PTSD and psychological distress in people with advanced thyroid cancer.
- What could go wrong
- This is a very small pilot study with only 25 participants, so results may not apply to everyone. It is early-stage research, not a proven treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 25 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Dec 2025
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 100 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * cancer diagnosis * PTSD (IES-R \> 32) Exclusion Criteria: * receiving specialized trauma therapy * receiving current psychiatric pharmacological treatment, unless the dosage has been stable for at least 2 months prior to enrollment
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Neoplasm are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Università Cattolica del Sacro Cuore
RECRUITINGMilan, 20123, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Does a camera lens offer a path to calmer minds?
- Can talk therapies quiet the trauma of violence?
- Could pausing psychiatric pills boost PTSD therapy?
- Tracing a cancer Drug's path through the body
- Can a new antibody help the immune system fight Hard-to-Treat tumors?
- Ancient music therapy put to the test against anxiety in pancreatic cancer